Welcome to our dedicated page for Protalix Biother SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Protalix BioTherapeutics, Inc. (PLX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a NYSE American–listed biopharmaceutical issuer focused on rare disease therapeutics and recombinant proteins produced via its ProCellEx® plant cell-based system, Protalix uses these filings to report material events, financial results, governance decisions and capital markets activities.
Investors can review Form 8-K filings that Protalix has used to announce quarterly financial and business results, clinical and regulatory updates for products such as Elfabrio® and PRX–115, changes in executive leadership, entry into or amendments of material agreements, and outcomes of legal or stockholder matters. Other SEC reports, including annual and quarterly reports, provide detailed discussions of revenue from sales of Elfabrio and Elelyso®, collaboration structures with partners like Chiesi, Pfizer and Fiocruz, and the status of development programs such as PRX–119.
For those monitoring corporate finance and ownership, this page also surfaces filings related to equity offerings and governance, such as amendments to at-the-market offering agreements and disclosures about stockholder meetings and executive compensation arrangements. Together, these documents help explain how Protalix funds its operations, manages risk and aligns management incentives.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy SEC documents, helping readers quickly understand the implications of Protalix’s 10-K and 10-Q reports, 8-K current reports and other submissions. Real-time updates from EDGAR ensure that new filings appear promptly, while structured access to transaction-related disclosures and governance items supports deeper due diligence on PLX.
Protalix BioTherapeutics (PLX) reported consolidated revenue of $25.8 million for the six months ended June 30, 2025, up from $17.2 million a year earlier, driven by product sales to Pfizer, Fiocruz and Chiesi. The company narrowed its six-month net loss to $3.5 million from $6.8 million a year ago and recorded a $0.16 million net income in the three months ended June 30, 2025. Cash and cash equivalents were $17.9 million with short-term bank deposits of $15.5 million, total assets of $78.5 million and stockholders' equity of $49.9 million.
The company generated $6.8 million net proceeds from at-the-market sales under the Sales Agreement during the six-month period and stated that cash and short-term deposits are sufficient to satisfy capital needs for at least 12 months. Commercial activities include marketed products Elfabrio and Elelyso with commercialization partners Chiesi and Pfizer, ongoing clinical programs (PRX-115, PRX-119) and manufacturing responsibilities for approved products. The filing also discloses potential operational exposure to the Israel conflict and steps taken to mitigate supply risk.
Protalix BioTherapeutics, Inc. disclosed that it furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and provided a business and clinical update. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K. The filing notes that the furnished information is not deemed "filed" under Section 18 of the Exchange Act and, therefore, is not incorporated by reference into registration statements or other filings unless specifically stated.
Protalix BioTherapeutics director Aharon Schwartz purchased 129,000 shares of Protalix (PLX) common stock on 06/10/2025 at a weighted average price of $1.596 per share, with execution prices ranging from $1.575 to $1.60 across multiple trades. Following the reported purchase, the reporting person beneficially owned 303,000 shares.
The filing identifies Mr. Schwartz as a director and shows the transaction coded as a purchase. The report notes the transaction was executed in multiple trades and that the reporting person will provide full trade-by-trade details upon request to the SEC staff, the issuer, or a security holder.
Protalix BioTherapeutics (NYSE:PLX) filed an 8-K disclosing the results of its 2025 Annual Meeting held on June 26, 2025.
- Eight directors elected: top nominee received 22.4 M votes for versus 1.9 M withheld; 12.7 M broker non-votes across the slate.
- Say-on-pay approved: 16.4 M for, 7.5 M against, 0.38 M abstentions, 12.7 M broker non-votes.
- PwC Israel ratified as auditor for FY 2025: 34.9 M for, 1.6 M against, 0.46 M abstentions.
No additional material actions or strategic updates were reported.